JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa.

BACKGROUND: Oral isotretinoin has been used to treat mild to severe hidradenitis suppurativa (HS).

OBJECTIVE: We reviewed the results of low-dose isotretinoin for 4 to 6 months in the treatment of 68 patients with HS.

METHODS: This is a retrospective study. Data are presented in terms of response rate, long-term follow-up, and the relation between response rate and severity.

RESULTS: In 16 patients (23.5%), the condition completely cleared during initial therapy and 11 patients (16.2%) maintained their improvement during the follow-up period. Treatment was more successful in the milder forms of HS.

CONCLUSION: Monotherapy with isotretinoin for patients with HS usually has a limited therapeutic effect.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app